Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Director Options

7 Jun 2011 16:21

Verona Pharma plc (the "Company") Director Options

The Company today announces, following a recommendation from the Company's Remuneration Committee, that on 7 June 2011, the Company extended the expiry date of existing Director options ("Options") over ordinary shares of 0.1 p each in the Company ("Ordinary Shares") as follows:-

Name of Position Total Number of Existing New expiry Director number of Options expiry date date Options subject to held change in expiry date Clive Page Chairman 2,000,000 2,000,000 18 September 18 September 2011 2016 Michael Chief 2,000,000 2,000,000 18 September 18 September Walker Executive 2011 2016 Officer Claire Poll Corporate 2,000,000 2,000,000 18 September 18 September Director 2011 2016

Stuart Non-Executive 2,000,000 2,000,000 18 September 18 September Bottomley Director

2011 2016

Trevor Non-Executive 2,000,000 2,000,000 18 September 18 September Jones Director

2011 2016

Apart from the extension of the expiry date, the above Options remain unchanged and continue to have an exercise price of 5 pence. The total number of Ordinary Shares under option held by Directors which could be issued if all of the performance criteria remains unchanged at 11,500,000, representing approximately 4.8 per cent. of the current issued share capital of the Company.

For more information please contact:

Verona Pharma plc Tel: 020 7863 3300Clive Page, Chairman info@veronapharma.comMichael Walker, CEO

Evolution Securities Limited (NOMAD and Joint Broker) Tel: 020 7071 4300 Bobbie Hilliam / Tim Redfern / Patrick Castle

contactus@evosecurities.comWH Ireland Group Plc (Joint Broker) Tel: 0121 265 6300Richard Smith / Nicola Rayner Richard.Smith@WH-Ireland.Co.UKCollege Hill Tel: 020 7457 2020Melanie Toyne Sewell / Gemma Howe verona@thecollegegroup.com

vendor
Date   Source Headline
13th Sep 20167:00 amPRNHalf-year Report
12th Sep 20167:00 amPRNAppointment of Vikas Sinha as Non-Executive Director
30th Aug 20167:00 amPRNData on RPL554 to be presented at ERS Congress
10th Aug 20169:59 amPRNNotice of Results
9th Aug 20162:16 pmRNSDirector Dealing
5th Aug 20169:27 amRNSHolding(s) in Company
4th Aug 20163:26 pmPRNGrant of Share Options
4th Aug 20168:45 amRNSHolding(s) in Company
3rd Aug 20169:03 amRNSHolding(s) in Company
3rd Aug 20168:43 amRNSHolding(s) in Company
3rd Aug 20168:37 amRNSHolding(s) in Company
2nd Aug 20164:26 pmRNSHolding(s) in Company - Replacement
2nd Aug 201611:26 amRNSHolding(s) in Company
1st Aug 20163:57 pmRNSHolding(s) in Company
1st Aug 201611:40 amRNSHolding(s) in Company
1st Aug 201611:20 amRNSHolding(s) in Company
29th Jul 20168:06 amPRNAdmission of Placing Shares
22nd Jul 201611:32 amPRNResult of GM
1st Jul 20168:00 amPRNNotice of GM
27th Jun 20161:42 pmPRNResult of AGM
20th Jun 20167:00 amPRNProposed Placing and Notice of General Meeting
17th Jun 20164:54 pmPRNProposed Placing and Notice of General Meeting
3rd Jun 20165:26 pmPRN2015 Annual Report and Accounts, Notice of AGM
3rd Jun 20167:00 amPRNFinal Results
27th May 20162:48 pmPRNNotice of Results
10th May 20167:00 amPRNAdd-on Phase II RPL554 study
4th May 20167:00 amPRNVerona to present RPL554 at the ATS Conference
19th Apr 20163:16 pmPRNChange of Registered Office
15th Apr 20164:08 pmRNSHolding(s) in Company
21st Mar 20167:00 amPRNVerona Pharma: 2015 in review
15th Mar 20167:00 amPRNPositive results from RPL554 dose-finding study
10th Feb 20162:47 pmPRNGrant of Share Options
21st Jan 201612:24 pmRNSDirector Dealing
11th Jan 20167:00 amPRNDirectorate Change
3rd Dec 20154:02 pmPRNDirector Dealing
1st Dec 20155:11 pmRNSHolding(s) in Company
11th Nov 20157:00 amPRNRPL554 paper published in American Journal of Physiology
5th Nov 20157:00 amPRNPatient enrolment completed in RPL554 PhIIa studies
14th Oct 20157:00 amPRNStart of RPL554 Phase IIa combination study
8th Oct 201511:30 amPRNRPL554 data presented at North American CF Conference
29th Sep 20157:00 amPRNPositive headline data from RPL554 study
8th Sep 20157:00 amPRNBoard Changes
8th Sep 20157:00 amPRNHalf-yearly Report
27th Aug 20157:00 amPRNNotice of Results
7th Jul 20154:45 pmPRNDirector Dealing
17th Jun 20155:02 pmPRNDirector Dealings
12th Jun 20157:00 amPRNSecondary listing in Germany
11th Jun 20151:00 pmPRNResult of AGM
11th Jun 20157:00 amPRNRPL554 Phase 2a trial started
8th Jun 20157:00 amPRNRPL554 MAD study complete

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.